tradingkey.logo
tradingkey.logo
Search

Qlaris Bio Announces First Patient Dosed in Phase II Nightingale Clinical Trial in Normal Tension Glaucoma Patients

ReutersAug 26, 2025 12:21 PM
facebooktwitterlinkedin

-

  • QLARIS BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE II NIGHTINGALE CLINICAL TRIAL IN NORMAL TENSION GLAUCOMA PATIENTS

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI